Virtual gene editing startup to lease Cambridge lab after $40M round
The company, Exonics Therapeutics, said the Series A round will allow it to hire scientists to conduct preclinical research into a potential treatment for Duchenne muscular dystrophy.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Max Stendahl Source Type: news
More News: American Health | Genetics | Health Management | Muscular Dystrophy | Reflex Sympathetic Dystrophy